<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Death Dis</journal-id><journal-id journal-id-type="iso-abbrev">Cell Death Dis</journal-id><journal-title-group><journal-title>Cell Death &#x00026; Disease</journal-title></journal-title-group><issn pub-type="epub">2041-4889</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39890803</article-id><article-id pub-id-type="pmc">PMC11785999</article-id><article-id pub-id-type="publisher-id">7376</article-id><article-id pub-id-type="doi">10.1038/s41419-025-07376-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Smad4 deficiency in hepatocytes attenuates NAFLD progression via inhibition of lipogenesis and macrophage polarization</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yan</surname><given-names>Xuanxuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xin</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ge</surname><given-names>Shuang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yongxiang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yan</surname><given-names>Xinlong</given-names></name><address><email>Yxlong2000@bjut.edu.cn</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8957-8893</contrib-id><name><surname>Zhang</surname><given-names>Jinhua</given-names></name><address><email>zhangjh@bjtu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01yj56c84</institution-id><institution-id institution-id-type="GRID">grid.181531.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1789 9622</institution-id><institution>The College of Life Science and Bioengineering, </institution><institution>Beijing Jiaotong University, </institution></institution-wrap>Beijing, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dveyr97</institution-id><institution-id institution-id-type="GRID">grid.256607.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 2653</institution-id><institution>National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targetubg Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-Targeting Theranostics, </institution><institution>Guangxi Medical University, </institution></institution-wrap>Nanning, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/037b1pp87</institution-id><institution-id institution-id-type="GRID">grid.28703.3e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9040 3743</institution-id><institution>Faculty of Environmental and Life Sciences, </institution><institution>Beijing University of Technology, </institution></institution-wrap>Beijing, China </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue>1</issue><elocation-id>58</elocation-id><history><date date-type="received"><day>31</day><month>5</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Nonalcoholic fatty liver disease (NAFLD), a major cause of chronic liver disorders, has become a serious public health issue. Although the Smad4 signaling pathway has been implicated in the progression of NAFLD, the specific role of Smad4 in hepatocytes in NAFLD pathogenesis remains unclear. Hepatocyte-specific knockout Smad4 mice (Alb<sup>Smad4&#x02212;/&#x02212;</sup>) were first constructed using the Cre-Loxp recombinant system to establish a high-fat diet induced NAFLD model. The role of Smad4 in the occurrence and development of NAFLD was determined by monitoring the body weight of mice, detecting triglycerides and free fatty acids in serum and liver tissue homogenates, staining the tissue sections to observe the accumulation of liver fat, and RT-qPCR detecting the expression of genes related to lipogenesis, fatty acid intake, and fatty acid &#x003b2; oxidation. The molecular mechanism of Smad4 in hepatocytes affecting NAFLD was therefore investigated through combining in vitro and in vivo experiments. Smad4 deficiency in hepatocytes mitigated NAFLD progression and decreased inflammatory cell infiltration. Moreover, Smad4 deficiency inhibited CXCL1 secretion by suppressing the activation of the ASK1/P38/JNK signaling pathway. Furthermore, targeting CXCL1 using CXCR2 inhibitors diminished hepatocyte lipogenesis and inhibited the polarization of M1-type macrophages. Collectively, these results suggested that Smad4 plays a vital role in exacerbating NAFLD and may be a promising candidate for anti-NAFLD therapy.</p><p id="Par2">
<graphic position="anchor" xlink:href="41419_2025_7376_Figa_HTML" id="d33e257"/>
</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Mechanisms of disease</kwd><kwd>Cytokines</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>81972689</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Jinhua</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004826</institution-id><institution>Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation)</institution></institution-wrap></funding-source><award-id>7232102</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Jinhua</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002888</institution-id><institution>Beijing Municipal Commission of Education (Beijing Municipal Education Commission)</institution></institution-wrap></funding-source><award-id>KZ202210005010</award-id><principal-award-recipient><name><surname>Yan</surname><given-names>Xinlong</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Associazione Differenziamento e Morte Cellulare ADMC 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Nonalcoholic fatty liver disease (NAFLD) is characterized by the excessive accumulation of lipids within hepatocytes, due to factors other than alcohol consumption and other definitive liver damage sources [<xref ref-type="bibr" rid="CR1">1</xref>]. NAFLD is a complex, multifactorial condition influenced by both environmental factors and genetic predispositions [<xref ref-type="bibr" rid="CR2">2</xref>]. It encompasses a spectrum of pathological liver conditions of varying severity, ranging from isolated hepatic steatosis (NAFL) to steatohepatitis (NASH), which can further progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [<xref ref-type="bibr" rid="CR3">3</xref>]. With an estimated prevalence in nearly one-third of the global adult population, NAFLD has become a public health concern [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par4">Hepatocytes, the main functional units of the liver, play a pivotal role in biotransformation, metabolism, and detoxification. During NAFLD progression, there is an excessive accumulation of triglyceride, free fatty acid (FFA), and cholesterol in hepatocytes, a process that is associated with insulin resistance that can lead to dysfunctional triglyceride synthesis and transport [<xref ref-type="bibr" rid="CR5">5</xref>]. The excessive lipid accumulation induces lipotoxicity, which impairs mitochondrial function, triggers endoplasmic reticulum (ER) stress, and triggers inflammatory responses in hepatocytes due to reactive oxygen species (ROS)-induced inflammation [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Concurrently, FFA accumulation in hepatocytes enhances mitochondrial &#x003b2;-oxidation, sensitizing the liver to oxidative stress and thereby exacerbating liver damage [<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, lipotoxicity can disrupt the JNK pathway and Toll-like receptor cellular signaling pathways, thereby affecting hepatocyte metabolism [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par5">Liver macrophages comprise recruited monocyte-derived macrophages and resident Kupffer cells within the liver. Liver macrophages play a central role in the regulation of hepatocyte metabolism and maintenance of hepatic immunological tolerance [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. They can promote the progression of metabolic diseases by enhancing insulin resistance, hepatic steatosis, and oxidative stress in obese mice and rats [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Under normal physiological conditions, liver macrophages exhibit a tendency toward the M2 phenotype, which suppresses inflammation by secreting interleukin (IL)-4 and IL-13 [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. However, during NAFLD progression, hepatic stellate cells (HSCs) activation triggers the secretion of pro-inflammatory cytokines, which increases the levels of lipopolysaccharide (LPS) in the blood. High levels of FFAs activate inflammasomes. These changes stimulate the onset of inflammation, with a concomitant increase in the proportion of M1 macrophages secreting pro-inflammatory cytokines [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par6">The transforming growth factor beta (TGF-&#x003b2;) signaling pathway plays important roles in biological processes of cell growth, apoptosis, migration, and cancer development and progression [<xref ref-type="bibr" rid="CR19">19</xref>]. Smad acts as a downstream signaling molecule in the TGF-&#x003b2; signaling pathway [<xref ref-type="bibr" rid="CR20">20</xref>]. In mammals, eight different SMADs are further divided into three distinct classes: R-Smad (Smad1, 2, 3, 5, and 8), Co-Smad (Smad4), and I-Smad (Smad6 and 7) [<xref ref-type="bibr" rid="CR21">21</xref>]. Smad4 is a central mediator of TGF-&#x003b2; signaling, which binds to nearly all Smad proteins regulated by activated receptors and helps regulate the expression of various downstream genes [<xref ref-type="bibr" rid="CR22">22</xref>]. Hepatocyte Smad4 expression levels increase progressively as normal liver tissue progresses to NAFLD and finally to NASH [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Smad4 deletion attenuates inflammation, fibrosis, and hepatocyte apoptosis in NASH [<xref ref-type="bibr" rid="CR20">20</xref>]. After the administration of high-fat diet (HFD), Smad4 deletion in pancreatic &#x003b2;-cells improves blood glucose levels, insulin secretion, and glucose tolerance in obese mice [<xref ref-type="bibr" rid="CR25">25</xref>]. Although other studies have investigated the role of Smad4 in liver disease, its specific molecular mechanism in hepatocytes in NAFLD remains unclear.</p><p id="Par7">In this study, we examined the specific role of Smad4 in NAFLD progression using a mouse model with hepatocyte-specific Smad4 deletion. Our findings revealed that Smad4 deficiency in hepatocytes attenuates NAFLD development. Moreover, hepatocyte Smad4 was found to amplify CXCL1 secretion by facilitating the activation of the ASK1/P38/JNK signaling pathway. CXCL1, in turn, promotes hepatocyte lipogenesis and macrophage M1-type polarization via CXCR2 binding.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Smad4 expression in hepatocytes is upregulated during NAFLD progression</title><p id="Par8">To elucidate the relationship between Smad4 expression and NASH, the expression of Smad4 in healthy liver and NASH tissues from patients was assessed by tissue microarray using immunohistochemistry. We observed that Smad4 expression was significantly upregulated in NASH tissues compared to that in healthy controls (Fig. <xref rid="Fig1" ref-type="fig">1A, B</xref>). Moreover, we analyzed the publicly available Gene Expression Omnibus dataset GSE164760 and compared Smad4 expression between healthy and NASH tissues. The analysis revealed a significant increase in Smad4 mRNA levels in the NASH group compared to healthy controls (Fig. <xref rid="Fig1" ref-type="fig">1C</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Smad4 expression in hepatocytes is upregulated during NAFLD progression.</title><p><bold>A</bold>, <bold>B</bold> Immunohistochemical staining of SMAD4 in a tissue microarray from NASH patients. <bold>A</bold> Representative Smad4 staining is shown Scale bar, 50&#x02009;&#x003bc;m. <bold>B</bold> Statistical analysis ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>C</bold> Boxplots showing Smad4 expression levels in the GEO dataset GSE164760. Healthy: n&#x02009;=&#x02009;6; NASH: n&#x02009;=&#x02009;74. <bold>D</bold> Schematic illustration of HFD-induced mouse nonalcoholic fatty liver disease (NAFLD) model. <bold>E</bold> Representative staining of Smad4 in mouse liver samples and statistical analysis Scale bar, 50&#x02009;&#x003bc;m ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>F</bold> Oil Red O staining, representative double staining, and statistical analysis of Albumin (green) and Smad4 (red) in mouse liver tissues. (HPF: High Power Field) Scale bar, 50&#x02009;&#x003bc;m ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001&#x02009;. <bold>G</bold> The expression levels of Smad4 protein in mouse NAFLD liver tissues were determined using Western blot analysis. Smad4 was normalized to GAPDH **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></caption><graphic xlink:href="41419_2025_7376_Fig1_HTML" id="d33e417"/></fig></p><p id="Par9">To corroborate these findings, we used a short-term HFD mouse model of NAFLD (Fig. <xref rid="Fig1" ref-type="fig">1D</xref>). Immunohistochemical staining demonstrated a significant upregulation of Smad4 expression in the hepatocytes of fatty liver tissues (Fig. <xref rid="Fig1" ref-type="fig">1E</xref>). Oil Red O staining revealed obvious vacuole of lipid droplets in the HFD group (Fig. <xref rid="Fig1" ref-type="fig">1F</xref>). Double immunofluorescence staining confirmed that Smad4 was expressed in most hepatocytes <bold>(</bold>Fig. <xref rid="Fig1" ref-type="fig">1F</xref>). Consistent with this, Western blot analysis indicated a significant increase in Smad4 protein levels in fatty liver tissues of HFD-treated mice (Fig. <xref rid="Fig1" ref-type="fig">1G</xref>).</p><p id="Par10">Collectively, these results suggest that Smad4 is activated in hepatocytes during NAFLD, indicating a potentially crucial role for Smad4 in NAFLD pathogenesis.</p></sec><sec id="Sec4"><title>Hepatocyte-specific deletion of Smad4 attenuates high-fat diet-induced non-alcoholic fatty liver disease</title><p id="Par11">To further investigate the role of Smad4 in hepatocytes during NAFLD, we used a conditional Smad4 deletion approach in murine hepatocytes, as previously described [<xref ref-type="bibr" rid="CR26">26</xref>]. We generated hepatocyte-specific Smad4 knockout mice (Albumin-cre; Smad4<sup>flox/flox</sup>, Alb<sup>Smad4&#x02212;/&#x02212;</sup>) by crossing mice carrying the Loxp-flanked Smad4 allele with Albumin-cre mice. The Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice were born at the expected Mendelian ratio, viable, and fertile. Smad4<sup>fl/fl</sup> littermates were used as controls. Smad4 deletion in primary hepatocytes of Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice was confirmed using double immunofluorescence staining and Western blot (Fig. <xref rid="Fig2" ref-type="fig">2A, B</xref>). In addition, Smad4 was expressed in non-hepatocyte cells of Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice (Supplementary Fig. <xref rid="MOESM3" ref-type="media">1A</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Hepatocyte-specific deletion of Smad4 attenuates high-fat diet-induced non-alcoholic fatty liver disease.</title><p>Smad4<sup>fl/fl</sup> and Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice were fed an HFD for 4 months to establish NAFLD model (n&#x02009;=&#x02009;5 per group). Data are representative of at least three independent experiments. <bold>A</bold> Representative double staining of Albumin (red) and Smad4 (green) in primary hepatocytes. Scale bars, 50&#x02009;&#x003bc;m. <bold>B</bold> The protein level of Smad4 in primary hepatocytes was determined by Western blot. <bold>C</bold> Body weight changes in Smad4<sup>fl/fl</sup> and Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice were monitored during the NAFLD model construction **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01. <bold>D</bold> Representative photographs of the liver specimens and liver weight to body weight ratio *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>E</bold> Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglycerides (TG), and non-esterified fatty acids (NEFA) levels *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>F</bold> Hepatic TG and NEFA levels **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>G</bold> Glucose tolerance test (GTT) in Smad4<sup>fl/fl</sup> and Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice fed an HFD for 4 months *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01. <bold>H</bold> Representative staining of hematoxylin and eosin (H&#x00026;E), Oil Red O staining, and double staining of Albumin(red) and Smad4 (green) in liver tissues. Scale bar, 50&#x02009;&#x003bc;m. <bold>I</bold> The protein levels of Smad4 in liver tissues were determined using Western blot analysis.</p></caption><graphic xlink:href="41419_2025_7376_Fig2_HTML" id="d33e538"/></fig></p><p id="Par12">To delineate the role of Smad4 in NAFLD, we established an HFD-induced NAFLD model using Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice and their control littermates. In response to HFD feeding, Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice demonstrated a less pronounced increase in both body and liver weight compared with control littermates (Fig. <xref rid="Fig2" ref-type="fig">2C, D</xref>). After 3 months of HFD, Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice displayed lower serum alanine aminotransferase (ALT), triglyceride (TG), and non-esterified fatty acid (NEFA) levels, while serum aspartate aminotransferase (AST) and total cholesterol (TC) levels were similar between Alb<sup>Smad4&#x02212;/&#x02212;</sup> and control mice (Fig. <xref rid="Fig2" ref-type="fig">2E</xref>). Furthermore, hepatic TG and NEFA levels were notably reduced in Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice compared with Smad4<sup>fl/fl</sup> mice (Fig. <xref rid="Fig2" ref-type="fig">2F</xref>). Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice also exhibited impaired glucose tolerance compared with Smad4<sup>fl/fl</sup> mice (Fig. <xref rid="Fig2" ref-type="fig">2G</xref>). The absence of Smad4 in hepatocytes in Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice was further validated using double immunofluorescence staining and Western blot (Fig. <xref rid="Fig2" ref-type="fig">2H, I</xref>). Deletion of Smad4 in hepatocytes resulted in decreased fat accumulation, as evidenced by hematoxylin and eosin and Oil Red O staining. No significant differences were observed between Alb<sup>Smad4&#x02212;/&#x02212;</sup> and Smad4<sup>fl/fl</sup> mice who were fed a normal diet (Fig. <xref rid="Fig2" ref-type="fig">2H</xref>). Collectively, these data suggest that hepatocyte-specific Smad4 deficiency attenuates the development of HFD-induced NAFLD.</p></sec><sec id="Sec5"><title>Smad4 deficiency in hepatocytes attenuated liver inflammation and CXCL1 secretion</title><p id="Par13">To investigate whether Smad4 modulates liver inflammatory cell infiltration and hepatocyte proliferation, we stained liver tissues of Alb<sup>Smad4&#x02212;/&#x02212;</sup> and Smad4<sup>fl/fl</sup> mice via immunofluorescence. The infiltration of F4/80<sup>+</sup> macrophages and CD11b<sup>+</sup> monocytes was diminished in Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice compared with that in Smad4<sup>fl/fl</sup> mice when fed an HFD. When fed the normal diet, immune cell infiltration was similar between Alb<sup>Smad4&#x02212;/&#x02212;</sup> and control mice (Fig. <xref rid="Fig3" ref-type="fig">3A</xref>). During NAFLD progression, activated chemokines evoke multiple cellular and tissue responses, including hepatocyte proliferation, activation, necrosis, angiogenesis, and immune cell recruitment [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Notably, CXCL1 is a key gene involved in NAFLD progression. Therefore, we examined CXCL1 expression in the livers of Alb<sup>Smad4&#x02212;/&#x02212;</sup> and Smad4<sup>fl/fl</sup> mice through double immunofluorescence staining. CXCL1 levels were significantly lower in the livers of Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice than those in Smad4<sup>fl/fl</sup> mice (Fig. <xref rid="Fig3" ref-type="fig">3B</xref>). This decrease in CXCL1 levels was further confirmed using quantitative reverse transcription polymerase chain reaction (RT-qPCR) in hepatocytes of NAFLD of Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice (Fig. <xref rid="Fig3" ref-type="fig">3C</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Smad4 deficiency in hepatocytes attenuated liver inflammation and CXCL1 secretion.</title><p>Smad4<sup>fl/fl</sup> and Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice were fed an HFD for 4 months to establish the NAFLD model (n&#x02009;=&#x02009;5 per group). Data are representative of at least three independent experiments. <bold>A</bold> Immunofluorescence detection and statistical analysis of F4/80, CD11b, and Gr1 expression in NAFLD liver tissues. Scale bar, 50&#x02009;&#x000b5;m **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>B</bold> Double immunofluorescence staining for CXCL1 (red) and Albumin (green) in liver tissue. Scale bar, 50&#x02009;&#x003bc;m ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>C</bold> The relative mRNA expression of CXCL1 in liver tissues was measured using RT-qPCR, *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>D</bold>&#x02013;<bold>I</bold> AML12 cells were transfected with si-NC or si-Smad4, respectively, cultured with BSA or palmitic acid (PA, 500&#x02009;&#x003bc;M) for 24&#x02009;h. <bold>D</bold> The protein levels of Smad4 in control si-NC and si-Smad4 AML12 cells were determined using Western blot. <bold>E</bold> Relative mRNA expression of CXCL1 was measured using RT-qPCR in AML12 cells *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>F</bold> ELISA verification of culture supernatants from AML12 cells *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>G</bold>&#x02013;<bold>I</bold> AML12 cells transfected with lentiviral vectors for control or Smad4 knockdown were then cultured with BSA or PA (500&#x02009;&#x003bc;M) for 24&#x02009;h. <bold>G</bold> Western blot analysis of Smad4 protein expression in sh-GFP and sh-Smad4 AML12 cells. <bold>H</bold> The mRNA levels of CXCL1 were measured by RT-qPCR in AML12 cells ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>I</bold> Secretory protein levels of CXCL1 in AML12 cell medium were determined using ELISA. **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></caption><graphic xlink:href="41419_2025_7376_Fig3_HTML" id="d33e707"/></fig></p><p id="Par14">To further clarify the function of Smad4 in hepatocytes, we knocked down Smad4 in AML12 cells using siRNA and verified Smad4 protein levels using Western blot (Fig. <xref rid="Fig3" ref-type="fig">3D</xref>). The cells were then treated with palmitic acid (PA) for 24&#x02009;h to simulate an in vitro NAFLD environment. RT-qPCR analysis revealed that Smad4 deficiency mitigated the PA-induced CXCL1 expression in hepatocytes (Fig. <xref rid="Fig3" ref-type="fig">3E</xref>). The protein expression level of CXCL1 was further analyzed using enzyme-linked immunosorbent assay (ELISA) with AML12-conditioned medium (CM). Smad4 deficiency partly reduced the secretion of CXCL1 in PA-induced AML12 CM (Fig. <xref rid="Fig3" ref-type="fig">3F</xref>).</p><p id="Par15">In addition, AML12 cells were transfected with a lentiviral vector to knock down Smad4, and the expression levels of Smad4 protein were measured using Western blot (Fig. <xref rid="Fig3" ref-type="fig">3G</xref>). In line with previous results, both the expression and secretion of CXCL1 in PA-stimulated Smad4-knockdown AML12 cells were significantly reduced compared to those in control cells (Fig. <xref rid="Fig3" ref-type="fig">3H, I</xref>). Taken together, these results suggest that hepatocyte-specific deletion of Smad4 lessens liver inflammation and CXCL1 secretion.</p></sec><sec id="Sec6"><title>Hepatocyte Smad4 promotes CXCL1 secretion via the ASK1-P38-JNK signaling pathway</title><p id="Par16">Previous studies have highlighted the involvement of the JNK and p38 MAPK cascades in the regulation of CXCL1 secretion [<xref ref-type="bibr" rid="CR29">29</xref>]. Accordingly, we examined the levels of total and phosphorylated proteins involved in ASK1, P38, and JNK signaling. We found that the expression of phosphorylated ASK1 (p-ASK1), p38 (p-p38), and JNK (p-JNK) was diminished in the liver tissue of HFD-treated Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice compared with Smad4<sup>fl/fl</sup> mice (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Hepatocyte Smad4 promotes CXCL1 secretion via the ASK1-P38-JNK signaling pathway.</title><p>Groups of Smad4<sup>fl/fl</sup> and Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice were fed an HFD for 4 months to establish the NAFLD model (n&#x02009;=&#x02009;5 per group). <bold>A</bold> The expression levels of p38, p-p38, JNK, p-JNK, ASK1, and p-ASK1 in the liver were measured using Western blot analysis. Protein densities were quantified using densitometry. Phospho-protein levels were normalized to the total protein levels *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>B</bold> The expression levels of p38, p-p38, JNK, p-JNK, ASK1, and p-ASK1 proteins were measured using Western blot analysis in si-NC and si-Smad4 AML12 cells treated with PA (500&#x02009;&#x003bc;M) for 24&#x02009;h. Phospho-proteins were normalized to total proteins *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>C</bold> The expression levels of p38, p-p38, JNK, p-JNK, ASK1, and p-ASK1 proteins were measured using Western blot analysis in sh-GFP and sh-Smad4 AML12 cells treated with PA (500&#x02009;&#x003bc;M) for 24&#x02009;h. Phospho-protein levels were normalized to total protein levels *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01. <bold>D</bold>, <bold>E</bold> After pretreatment of AML12 cells with SB203580 (P38 MAPK inhibitor) or SP600125 (JNK inhibitor) for 2&#x02009;h, 500&#x02009;&#x003bc;M PA was co-incubated for 24&#x02009;h. <bold>D</bold> The mRNA levels of CXCL1 were measured using RT-qPCR in AML12 cells ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>E</bold> Secretory protein levels of CXCL1 were measured using ELISA in AML12 cells *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="41419_2025_7376_Fig4_HTML" id="d33e797"/></fig></p><p id="Par17">In subsequent experiments, we used si-Smad4 and sh-Smad4 to knock down Smad4 in AML12 cells, which were then exposed to PA. The Western blot analysis showed that the ASK1, P38, and JNK signaling pathways were activated in hepatocytes in response to PA administration. However, this activation was remarkably suppressed by Smad4 knockdown, suggesting that Smad4 knockdown considerably inhibited PA-induced activation of the ASK1&#x02013;P38&#x02013;JNK pathway in vitro (Fig. <xref rid="Fig4" ref-type="fig">4B, C</xref>).</p><p id="Par18">To further elucidate the signaling pathways involved in the induction of CXCL1 secretion by Smad4, we employed the JNK inhibitor (SP600125) and the p38 MAPK inhibitor (SB203580). Both inhibitors suppressed PA-induced CXCL1 secretion and mRNA expression, as evidenced using RT&#x02013;qPCR and ELISA analysis (Fig. <xref rid="Fig4" ref-type="fig">4D, E</xref>). In conclusion, these results suggest that Smad4 facilitates CXCL1 secretion via the ASK1-P38-JNK signaling pathways during NAFLD progression.</p></sec><sec id="Sec7"><title>CXCL1 promotes fatty acid synthesis in hepatocytes by binding to CXCR2</title><p id="Par19">To further investigate the role of Smad4 in hepatic lipid deposition, RT-qPCR was used to determine the expression levels of genes involved in fatty acid synthesis and consumption. We found that Smad4 deficiency considerably inhibited the expression of genes critical for fatty acid synthesis (ACC1, FASN, and SCD1) and fatty acid binding protein 1 (FABP1). However, we observed no substantial differences in the expression of genes related to fatty acid uptake (FATP1) and fatty acid &#x003b2;-oxidation (CPT1a and ACOX1) (Fig. <xref rid="Fig5" ref-type="fig">5A</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><title>CXCL1 promotes fatty acid synthesis in hepatocytes by binding to CXCR2.</title><p>Groups of Smad4<sup>fl/fl</sup> and Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice were fed an HFD for 4 months to establish the NAFLD model (n&#x02009;=&#x02009;5 per group). <bold>A</bold> The mRNA levels of ACC1, FASN, SCD1, FABP1, FATP1, ACOX1, and CPT1a in NAFLD liver tissues were measured using RT-qPCR analysis *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01. <bold>B</bold>&#x02013;<bold>G</bold> Primary hepatocytes and AML12 cells were treated with BSA or PA (500&#x02009;&#x003bc;M) for 24&#x02009;h. <bold>B</bold> The mRNA levels of ACC1, FASN, and PPAR&#x003b3; in primary hepatocytes were determined using RT-qPCR analysis *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>C</bold> Oil Red O staining of primary hepatocytes. Scale bar, 100&#x02009;&#x003bc;m. <bold>D</bold> The mRNA levels of ACC1, FASN, and SCD1 were determined using RT-qPCR analysis in AML12 cells with si-NC or si-Smad4 transfection *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01. <bold>E</bold> Oil Red O staining of AML12 cells transfected with si-NC or si-Smad4. Scale bar, 10&#x02009;&#x003bc;m. <bold>F</bold> The mRNA levels of ACC1, FASN, and SCD1 were determined using RT-qPCR analysis in AML12 cells transfected with sh-GFP or sh-Smad4 *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01. <bold>G</bold> Oil Red O staining of AML12 cells transfected with sh-GFP or sh-Smad4, respectively. Scale bar, 10&#x02009;&#x003bc;m. <bold>H</bold> The protein levels of CXCR2 in AML12 cells treated with 50&#x02009;ng/mL CXCL1 were detected by Western blot. <bold>I</bold> AML12 cells were cultured with 500&#x02009;&#x003bc;M PA, 50&#x02009;ng/mL CXCL1 recombinant protein, and 500&#x02009;nM SB225002 (inhibitor of CXCL1 receptor CXCR2) for 24&#x02009;h. The mRNA levels of ACC1, FASN, and SCD1 were determined using RT-qPCR analysis in AML12 cells *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="41419_2025_7376_Fig5_HTML" id="d33e897"/></fig></p><p id="Par20">To corroborate these findings, we isolated primary hepatocytes from Alb<sup>Smad4&#x02212;/&#x02212;</sup> and Smad4<sup>fl/fl</sup> mice and then exposed them to PA. Following Smad4 knockout, the expression of genes responsible for fatty acid synthesis (ACC1, FASN, and PPAR-&#x003b3;) was substantially reduced in primary hepatocytes (Fig. <xref rid="Fig5" ref-type="fig">5B</xref>). We further observed decreased lipid deposition in primary hepatocytes of Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice compared with that in Smad4<sup>fl/fl</sup> mice following PA treatment, as evidenced by Oil Red O staining <bold>(</bold>Fig. <xref rid="Fig5" ref-type="fig">5C</xref><bold>)</bold>. This conclusion was confirmed using si-Smad4 AML12 and sh-Smad4 AML12 cells (Fig. <xref rid="Fig5" ref-type="fig">5D&#x02013;G</xref>). Taken together, these findings suggest that hepatocyte Smad4 promotes NAFLD development primarily through fatty acid synthesis.</p><p id="Par21">CXCL1 binds to specific receptor CXCR2. We then examined whether CXCL1-induced fatty acid synthesis occured in hepatocytes. We assessed the expression levels of CXCR2 in hepatocytes using Western blot (Fig. <xref rid="Fig5" ref-type="fig">5H</xref>). To further elucidate the molecular mechanisms underlying the effects of CXCL1 on fatty acid synthesis, we cultured AML12 cells with CXCL1 recombinant protein and analyzed the expressions of genes related to fatty acid synthesis using RT-qPCR. We observed that ACC1, FASN, and SCD1 were substantially upregulated by CXCL1. However, when CXCR2 activation was inhibited by the CXCR2 inhibitor, SB225002, in AML12 cells, CXCL1-induced ACC1, FASN, and SCD1 expression was reduced (Fig. <xref rid="Fig5" ref-type="fig">5I</xref>). These results suggest that CXCL1 induces fatty acid synthesis in hepatocytes via CXCR2.</p></sec><sec id="Sec8"><title>CXCL1 promotes macrophage M1 polarization</title><p id="Par22">Aberrant lipid-mediated hepatic inflammatory-immune dysfunction and chronic low-grade inflammation play important roles in NAFLD pathogenesis. Macrophage polarization is an important mechanism that regulates inflammatory responses [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, we assessed the quantities of CD86<sup>+</sup> (M1 marker) and CD206<sup>+</sup> (M2 marker) macrophages in NAFLD tissues. Our findings revealed a substantial decrease in M1 macrophages in Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice compared with Smad4<sup>fl/fl</sup> mice, while M2-like macrophages remained comparable (Fig. <xref rid="Fig6" ref-type="fig">6A, B</xref>). We further evaluated the expression levels of genes associated with M1-like (IL-6, MCP1, and TNF-&#x003b1;) and M2-like (Arg1, IL-10, and YM1) phenotypes using RT-qPCR and found similar results (Fig. <xref rid="Fig6" ref-type="fig">6C, D</xref>). Given that the absence of hepatocyte Smad4 resulted in diminished CXCL1 secretion, we postulated that hepatocyte Smad4 might facilitate macrophage M1 polarization via CXCL1. We confirmed the expression of CXCR2 in macrophages using western blot (Fig. <xref rid="Fig6" ref-type="fig">6E</xref>). We cultured RAW264.7 cells with LPS and IFN-&#x003b3; for 24&#x02009;h to induce M1 polarization. It was found that LPS and IFN-&#x003b3; activated the expression of CD86 in macrophages in comparison with the control group, CXCL1 recombinant proteins further upregulated CD86. This expression was further augmented by the addition of CXCL1 recombinant proteins, as evidenced by immunofluorescence staining. However, the treatment of RAW264.7 cells with the CXCR2 inhibitor SB225002 eliminated CXCL1-induced expression of CD86 (Fig. <xref rid="Fig6" ref-type="fig">6F</xref>). Following M1 polarization induction, the expression levels of iNOS, MCP1, and TNF-&#x003b1; were significantly increased in RAW264.7 cells compared with those in the control group, and the addition of exogenous CXCL1 recombinant protein further amplified M1-related gene expression (Fig. <xref rid="Fig6" ref-type="fig">6G</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><title>CXCL1 promotes macrophage M1 polarization.</title><p>Smad4<sup>fl/fl</sup> and Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice were fed an HFD for 4 months to establish the NAFLD model (n&#x02009;=&#x02009;5 per group). Data are representative of at least three independent experiments. <bold>A</bold>, <bold>B</bold> Representative staining and statistical analysis of CD86 and CD206 expression in liver tissues Scale bar, 50&#x02009;&#x003bc;m. <bold>C</bold>, <bold>D</bold> The mRNA levels of IL-6, MCP1, TNF-&#x003b1;, Arg1, IL-10, and YM1 in liver tissues were determined using RT-qPCR analysis *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01. <bold>E</bold> The protein levels of CXCR2 in Raw264.7 cells treated with 50&#x02009;ng/mL CXCL1 were detected by Western blot. <bold>F</bold>, <bold>G</bold> Raw264.7 cells were cultured with 100&#x02009;ng/mL LPS, 10&#x02009;ng/mL IFN-&#x003b3;, 50&#x02009;ng/mL CXCL1 recombinant protein, and 500&#x02009;nM SB225002 for 24&#x02009;h. <bold>F</bold> Immunofluorescence staining of CD86 in RAW264.7 cells Scale bar, 50&#x02009;&#x003bc;m. <bold>G</bold> The mRNA levels of iNOS, MCP1, and TNF-&#x003b1; in RAW264.7 cells were determined using RT-qPCR analysis *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 and ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>H</bold> Raw264.7 cells were cultured with 20&#x02009;ng/mL IL-4, 20&#x02009;ng/mL IL-13, 50&#x02009;ng/mL CXCL1 recombinant protein, and 500&#x02009;nM SB225002 for 48&#x02009;h. The mRNA levels of Arg1, IL-10, and YM1 in RAW264.7 cells were determined using RT-qPCR analysis ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="41419_2025_7376_Fig6_HTML" id="d33e1025"/></fig></p><p id="Par23">For M2 polarization, RAW264.7 cells were cultured with IL-4 and IL-13 for 48&#x02009;h. This treatment activated the expression of Arg1, IL-10, and YM1 in macrophages compared with the control group. No significant differences were observed after the administration of CXCL1 and SB225002 (Fig. <xref rid="Fig6" ref-type="fig">6H</xref>). These findings suggest that CXCL1 promotes the M1-type polarization of macrophages via CXCR2.</p></sec></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p id="Par24">Smad4 is a general mediator of the TGF-&#x003b2; and bone morphogenetic protein (BMP) signaling pathways, which significantly contribute to intracellular signal transduction and a myriad of cellular processes [<xref ref-type="bibr" rid="CR19">19</xref>]. However, owing to its ubiquitous expression, the specific role and molecular mechanism of Smad4-mediated signaling in NAFLD progression remain elusive. Our study illustrated that hepatocyte-specific Smad4 expression promoted NAFLD development by enhancing CXCL1 secretion. Targeted deficiency of hepatocyte-specific Smad4 signaling curbed the progression of NAFLD in HFD-fed mice. Hepatocyte-specific genetic deficiency of Smad4 inhibited fatty acid synthesis and macrophage M1 polarization. Moreover, Smad4 in hepatocytes accelerated CXCL1 secretion to enhance fatty acid synthesis and macrophage M1 polarization by activating the ASK-P38-JNK signaling pathway.</p><p id="Par25">NAFLD is now recognized as a steatotic liver disease closely associated with metabolic syndrome. The relationship between NAFLD and liver inflammation has been extensively studied. Several studies indicate the pivotal role of TGF-&#x003b2;/Smad signaling in metabolic syndrome and related disorders [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Our results suggested that Smad4 is activated in hepatocytes during NAFLD <bold>(</bold>Fig. <xref rid="Fig1" ref-type="fig">1</xref>). We found that there was no difference in Smad4 nucleus expression between ND and HFD groups detected by Western blot in vivo (Supplementary Fig. <xref rid="MOESM3" ref-type="media">2A</xref>). Similar results were obtained by using AML12 cells. In addition, the stimulation of TGF-&#x003b2; didn&#x02019;t change Smad4 expression <bold>(</bold>Supplementary Fig. <xref rid="MOESM3" ref-type="media">2B</xref><bold>)</bold>. Therefore, Smad4 activation didn&#x02019;t depend on TGF-&#x003b2; <bold>(</bold>Supplementary Fig. <xref rid="MOESM3" ref-type="media">2A, B</xref><bold>)</bold>. Our previous study demonstrated that the targeted knockout of Smad4 in hepatocytes attenuates hepatic inflammatory cell infiltration and fibrosis during the progression of CCl<sub>4</sub> induced liver fibrosis [<xref ref-type="bibr" rid="CR26">26</xref>]. Disruption of the Smad4 pathway alleviated spontaneous liver injury, hepatic inflammatory cell infiltration, fibrosis, and HCC induced by TAK1 deletion in hepatocytes [<xref ref-type="bibr" rid="CR33">33</xref>]. Kundu et al. confirmed that the SIRT4/SMAD4 axis played a vital role in HFD-fed induced liver fibrosis. Upregulation of SIRT4 and downregulation of Smad4 can potentially counteract lipid accumulation, inflammation, and fibrosis during NAFLD progression [<xref ref-type="bibr" rid="CR34">34</xref>]. Hepatocyte-specific deletion of Smad4 markedly reduced the expression of fibrosis, hepatocyte apoptosis-, and inflammation-related genes during NASH progression [<xref ref-type="bibr" rid="CR20">20</xref>]. Collectively, our results support this conclusion and demonstrate that hepatocyte-specific Smad4 deficiency alleviates HFD-fed induced NAFLD.</p><p id="Par26">Hepatocytes comprise the largest number of parenchymal cells in the liver and are the primary undertakers of liver function. With little or no alcohol intake, steatosis in more than 5% of hepatocytes is diagnosed as NAFLD [<xref ref-type="bibr" rid="CR35">35</xref>]. Increased lipid influx into the liver or reduced lipid disposal precipitates hepatic steatosis, primarily instigated by a HFD, genetic predisposition, gut microbiota, and upregulated expression of lipid transcription factors (e.g, SREBP1c, chREBP, and PPAR-&#x003b3;) [<xref ref-type="bibr" rid="CR36">36</xref>]. Abnormal accumulation of lipotoxic lipids, including fatty acids, diacylglycerols, and cholesterol in the liver, induces hepatocellular injury, including lipotoxicity, mitochondrial dysfunction, oxidative stress, ER stress, and severe inflammatory responses [<xref ref-type="bibr" rid="CR37">37</xref>]. Our results revealed that Smad4 deficiency in hepatocytes curtailed the secretion of CXCL1, which consequently mitigated hepatocyte fatty acid synthesis and macrophage M1 polarization.</p><p id="Par27">A recent integrative analysis of mild and severe NAFLD identified CXCL1 as one of the five hub genes. In vitro and in vivo experiments demonstrated that high-fat conditions increased CXCL1 levels in both the liver tissue and hepatocytes, which correlated with the duration of HFD feeding and PA concentration, consistent with our findings [<xref ref-type="bibr" rid="CR28">28</xref>]. CXCL1 is an important chemokine that is implicated in the progression of numerous inflammatory diseases [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. In the liver, CXCL1 is predominantly expressed in hepatocytes, with lower level expression in HSCs and liver-sinusoidal endothelial cells [<xref ref-type="bibr" rid="CR40">40</xref>]. CXCL1 primarily binds to the receptor CXCR2 and recruits neutrophils to inflammation sites. Previous studies have shown that CXCL1 chemokines are induced and released by the P38 MAPK and JNK signaling pathways in human pulmonary epithelial cells and vascular endothelial cells [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. In this study, we demonstrated that hepatocyte Smad4 expression stimulated CXCL1 secretion via the ASK1, P38 MAPK, and JNK signaling pathways, thereby promoting the progression of NAFLD. However, the potential role of CXCL1 on hepatocytes via other pathways warrants further investigation.</p><p id="Par28">M1 macrophages are key players in chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. Macrophages play a significant role in NAFLD pathogenesis, as evidenced by the prevention of inflammatory cell recruitment, hepatic steatosis, and hepatic insulin resistance in Kupffer cell -depleted mice [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In the NAFLD environment, macrophages are regulated by various molecular signals to polarize toward the M1 phenotype [<xref ref-type="bibr" rid="CR46">46</xref>]. Cytokines secreted by M1 liver macrophages are also likely to repress fatty acid oxidation and potentiate triglyceride synthesis [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. In line with this, we demonstrated that Smad4 deficiency in hepatocytes inhibits the transition of macrophages to the M1 phenotype in an NAFLD model. Interestingly, the secretion of CXCL1 does not affect macrophage M2 polarization. CXCL1 has been reported to play a crucial role in M1 macrophage polarization during cerebral aneurysm development [<xref ref-type="bibr" rid="CR49">49</xref>]. Consistent with this, our study showed that hepatocyte Smad4 promoted macrophage M1 polarization by facilitating CXCL1 secretion. Whether Smad4 influences NAFLD via other molecular mechanisms remains unclear.</p><p id="Par29">In conclusion, our study revealed that Smad4 expression in hepatocytes plays a crucial role in the development of NAFLD. Smad4 in hepatocytes amplified lipid accumulation and M1 macrophage polarization by stimulating CXCL1 secretion, thereby promoting NAFLD progression. Smad4 in hepatocytes may represent a potential preventive and therapeutic target for NAFLD.</p></sec><sec id="Sec10" sec-type="materials|methods"><title>Materials and Methods</title><p id="Par30">Some detailed information was provided in supplementary data. The details of RT-qPCR primers are described in supplementary material, Table <xref rid="MOESM1" ref-type="media">S1</xref>.</p><sec id="Sec11"><title>Mice</title><p id="Par31">Smad4<sup>flox/flox</sup> and Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice on a C57BL/6 background have been described previously [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Mice with a conditional knockout of Smad4 in hepatocytes expressing Albumin (Alb<sup>Smad4&#x02212;/&#x02212;</sup>) were generated by crossing Alb-Cre and Smad4<sup>flox/flox</sup> mice. The mice in the control group are cre-negative littermates. All mice were maintained in specific pathogen-free and humidity- and temperature-controlled microisolator cages with a 12-h light/dark cycle at the Institute of Biophysics, Chinese Academy of Sciences. Alb<sup>Smad4&#x02212;/&#x02212;</sup> mice and their littermate control mice which are used for the experiments were 5&#x02013;6 weeks old.</p></sec><sec id="Sec12"><title>HFD-induced NAFLD model</title><p id="Par32">The NAFLD model was administered in mice by feeding an HFD (60% of total energy from fat, Huafukang, Beijing, CN) continuously for 16 weeks. Mice that were administered a normal chow diet (ND, 10% of total energy from fat, Huafukang, Beijing, CN) served as controls.</p></sec><sec id="Sec13"><title>Cell lines and treatment</title><p id="Par33">The AML12 and RAW264.7 cell lines were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The AML12 cell was cultured in DMEM/F12 medium (Gibco, Grand Island US) supplemented with 10% fetal bovine serum (FBS, PAN biotech, Adenbach, Germany), 1% penicillin/ streptomycin, 40&#x02009;ng/mL dexamethasone (Solarbio, Beijing, China), and 1% insulin-transferrin-selenium (ITS, Procell, Wuhan, China). The RAW264.7 cell was cultured in DMEM/ 1640 supplemented with 10% FBS and 1% penicillin/ streptomycin. The cells were cultured at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub>. AML12 cells were exposed to palmitic acid (500&#x02009;&#x003bc;M) (Sigma, USA) for 24&#x02009;h. AML12 cells were treated with inhibitor of P38 MAPK SB203580 (10&#x02009;&#x003bc;M) (MedChemExpress, Princeton, NJ, USA) and inhibitor of JNK for SP600125 (10&#x02009;&#x003bc;M) (MedChemExpress, Princeton, NJ, USA) for 2&#x02009;h in advance. After incubation, the AML12 cells were challenged with 50&#x02009;ng/mL CXCL1 recombinant protein (Sino Biological, Beijing, China) for 24&#x02009;h for further analysis. AML12 and RAW264.7 cells were stimulated with 50&#x02009;ng/mL CXCL1 recombinant protein and 500&#x02009;nM inhibitor of CXCL1 receptor CXCR2 SB225002 (MedChemExpress, Princeton, NJ, USA) for 24&#x02009;h for further analysis.</p></sec><sec id="Sec14"><title>Statistical analysis</title><p id="Par34">All data were expressed as the mean&#x02009;&#x000b1;&#x02009;SEM and analyzed using GraphPad Prism V8.0.2 software. Significant differences between mean values were obtained from three independent experiments. Differences between the two groups were compared using two-tailed unpaired Student&#x02019;s t-test analysis. Two-way ANOVA was used for multiple comparisons. P&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41419_2025_7376_MOESM1_ESM.docx"><caption><p>Table S1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41419_2025_7376_MOESM2_ESM.pdf"><caption><p>Original Western blot</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41419_2025_7376_MOESM3_ESM.pdf"><caption><p>Supplemental material</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p>Edited by Yufang Shi</p></fn><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Wei Yang, Xuanxuan Yan.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41419-025-07376-8.</p></sec><notes notes-type="author-contribution"><title>Author contributions</title><p>JZ conceived and supervised the study. WY, XY, RC, XX, and SG conducted experiments. JZ, WY, XY, and YZ performed data analysis. JZ and WY wrote the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (81972689), the Natural Science Foundation of Beijing (7232102), and the R&#x00026;D program of Beijing Municipal Education Commission (KZ202210005010).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in this article and its online supplementary material. Further inquiries can be directed to the corresponding author.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par35">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par36">All animal studies were performed after approval by the Institutional Laboratory Animal Care and Use Committee of the Institute of Biophysics, Chinese Academy of Sciences.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Azzimato V, Jager J, Chen P, Morgantini C, Levi L, Barreby E, et al. Liver macrophages inhibit the endogenous antioxidant response in obesity-associated insulin resistance. Sci Transl Med. 2020;12:eaaw9709.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Younossi</surname><given-names>Z</given-names></name><name><surname>Anstee</surname><given-names>QM</given-names></name><name><surname>Marietti</surname><given-names>M</given-names></name><name><surname>Hardy</surname><given-names>T</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Eslam</surname><given-names>M</given-names></name><etal/></person-group><article-title>Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2018</year><volume>15</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2017.109</pub-id><pub-id pub-id-type="pmid">28930295</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11&#x02013;20.<pub-id pub-id-type="pmid">28930295</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Neuschwander-Tetri</surname><given-names>BA</given-names></name><name><surname>Rinella</surname><given-names>M</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><article-title>Mechanisms of NAFLD development and therapeutic strategies</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><fpage>908</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0104-9</pub-id><pub-id pub-id-type="pmid">29967350</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908&#x02013;22.<pub-id pub-id-type="pmid">29967350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Byrne</surname><given-names>CD</given-names></name><name><surname>Tilg</surname><given-names>H</given-names></name></person-group><article-title>NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>1691</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-320622</pub-id><pub-id pub-id-type="pmid">32321858</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691&#x02013;705.<pub-id pub-id-type="pmid">32321858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Pouwels</surname><given-names>S</given-names></name><name><surname>Sakran</surname><given-names>N</given-names></name><name><surname>Graham</surname><given-names>Y</given-names></name><name><surname>Leal</surname><given-names>A</given-names></name><name><surname>Pintar</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss</article-title><source>BMC Endocr Disord</source><year>2022</year><volume>22</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s12902-022-00980-1</pub-id><pub-id pub-id-type="pmid">35287643</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22:63.<pub-id pub-id-type="pmid">35287643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Browning</surname><given-names>JD</given-names></name><name><surname>Horton</surname><given-names>JD</given-names></name></person-group><article-title>Molecular mediators of hepatic steatosis and liver injury</article-title><source>J Clin Investig</source><year>2004</year><volume>114</volume><fpage>147</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1172/JCI200422422</pub-id><pub-id pub-id-type="pmid">15254578</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Investig. 2004;114:147&#x02013;52.<pub-id pub-id-type="pmid">15254578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>McLenithan</surname><given-names>JC</given-names></name><name><surname>Gong</surname><given-names>DW</given-names></name><name><surname>Yang</surname><given-names>RZ</given-names></name><etal/></person-group><article-title>Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>2037</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.2337/db07-1383</pub-id><pub-id pub-id-type="pmid">18487449</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bell M, Wang H, Chen H, McLenithan JC, Gong DW, Yang RZ, et al. Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance. Diabetes. 2008;57:2037&#x02013;45.<pub-id pub-id-type="pmid">18487449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Tiniakos</surname><given-names>DG</given-names></name><name><surname>Vos</surname><given-names>MB</given-names></name><name><surname>Brunt</surname><given-names>EM</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease: pathology and pathogenesis</article-title><source>Annu Rev Pathol</source><year>2010</year><volume>5</volume><fpage>145</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-121808-102132</pub-id><pub-id pub-id-type="pmid">20078219</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145&#x02013;71.<pub-id pub-id-type="pmid">20078219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>MV</given-names></name><name><surname>Diehl</surname><given-names>AM</given-names></name></person-group><article-title>Pathogenesis of nonalcoholic steatohepatitis</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><fpage>1769</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.02.066</pub-id><pub-id pub-id-type="pmid">26928243</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150:1769&#x02013;77.<pub-id pub-id-type="pmid">26928243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Rehman</surname><given-names>H</given-names></name><name><surname>Krishnasamy</surname><given-names>Y</given-names></name><name><surname>Ramshesh</surname><given-names>VK</given-names></name><name><surname>Theruvath</surname><given-names>TP</given-names></name><name><surname>Chavin</surname><given-names>KD</given-names></name><etal/></person-group><article-title>Role of inducible nitric oxide synthase in mitochondrial depolarization and graft injury after transplantation of fatty livers</article-title><source>Free Radic Biol Med</source><year>2012</year><volume>53</volume><fpage>250</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.05.012</pub-id><pub-id pub-id-type="pmid">22609250</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Liu Q, Rehman H, Krishnasamy Y, Ramshesh VK, Theruvath TP, Chavin KD, et al. Role of inducible nitric oxide synthase in mitochondrial depolarization and graft injury after transplantation of fatty livers. Free Radic Biol Med. 2012;53:250&#x02013;9.<pub-id pub-id-type="pmid">22609250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>BA</given-names></name><name><surname>Rezende</surname><given-names>RM</given-names></name><name><surname>Antunes</surname><given-names>MM</given-names></name><name><surname>Santos</surname><given-names>MM</given-names></name><name><surname>Freitas Lopes</surname><given-names>MA</given-names></name><name><surname>Diniz</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice</article-title><source>Gastroenterology</source><year>2016</year><volume>151</volume><fpage>1176</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.08.024</pub-id><pub-id pub-id-type="pmid">27569723</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">David BA, Rezende RM, Antunes MM, Santos MM, Freitas Lopes MA, Diniz AB, et al. Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice. Gastroenterology. 2016;151:1176&#x02013;91.<pub-id pub-id-type="pmid">27569723</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>De Baetselier</surname><given-names>P</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Saeys</surname><given-names>Y</given-names></name><name><surname>De Prijck</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>10321</fpage><pub-id pub-id-type="doi">10.1038/ncomms10321</pub-id><pub-id pub-id-type="pmid">26813785</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Scott CL, Zheng F, De Baetselier P, Martens L, Saeys Y, De Prijck S, et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun. 2016;7:10321.<pub-id pub-id-type="pmid">26813785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Metlakunta</surname><given-names>A</given-names></name><name><surname>Dedousis</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Sipula</surname><given-names>I</given-names></name><name><surname>Dube</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><fpage>347</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.2337/db09-0016</pub-id><pub-id pub-id-type="pmid">19934001</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes. 2010;59:347&#x02013;57.<pub-id pub-id-type="pmid">19934001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Neyrinck</surname><given-names>AM</given-names></name><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>Dewulf</surname><given-names>EM</given-names></name><name><surname>De Backer</surname><given-names>F</given-names></name><name><surname>Bindels</surname><given-names>LB</given-names></name><name><surname>Delzenne</surname><given-names>NM</given-names></name></person-group><article-title>Critical role of Kupffer cells in the management of diet-induced diabetes and obesity</article-title><source>Biochem Biophys Res Commun</source><year>2009</year><volume>385</volume><fpage>351</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.05.070</pub-id><pub-id pub-id-type="pmid">19463788</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Neyrinck AM, Cani PD, Dewulf EM, De Backer F, Bindels LB, Delzenne NM. Critical role of Kupffer cells in the management of diet-induced diabetes and obesity. Biochem Biophys Res Commun. 2009;385:351&#x02013;6.<pub-id pub-id-type="pmid">19463788</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>LJ</given-names></name><name><surname>Barnes</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Pritchard</surname><given-names>MT</given-names></name><name><surname>Nagy</surname><given-names>LE</given-names></name></person-group><article-title>Kupffer cells in the liver</article-title><source>Compr Physiol</source><year>2013</year><volume>3</volume><fpage>785</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1002/cphy.c120026</pub-id><pub-id pub-id-type="pmid">23720329</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol. 2013;3:785&#x02013;97.<pub-id pub-id-type="pmid">23720329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Hritz</surname><given-names>I</given-names></name><name><surname>Mandrekar</surname><given-names>P</given-names></name><name><surname>Velayudham</surname><given-names>A</given-names></name><name><surname>Catalano</surname><given-names>D</given-names></name><name><surname>Dolganiuc</surname><given-names>A</given-names></name><name><surname>Kodys</surname><given-names>K</given-names></name><etal/></person-group><article-title>The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><fpage>1224</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/hep.22470</pub-id><pub-id pub-id-type="pmid">18792393</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology. 2008;48:1224&#x02013;31.<pub-id pub-id-type="pmid">18792393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Csak</surname><given-names>T</given-names></name><name><surname>Ganz</surname><given-names>M</given-names></name><name><surname>Pespisa</surname><given-names>J</given-names></name><name><surname>Kodys</surname><given-names>K</given-names></name><name><surname>Dolganiuc</surname><given-names>A</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name></person-group><article-title>Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><fpage>133</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1002/hep.24341</pub-id><pub-id pub-id-type="pmid">21488066</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133&#x02013;44.<pub-id pub-id-type="pmid">21488066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Benkdane</surname><given-names>M</given-names></name><name><surname>Teixeira-Clerc</surname><given-names>F</given-names></name><name><surname>Bonnafous</surname><given-names>S</given-names></name><name><surname>Louvet</surname><given-names>A</given-names></name><name><surname>Lafdil</surname><given-names>F</given-names></name><etal/></person-group><article-title>M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><fpage>130</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/hep.26607</pub-id><pub-id pub-id-type="pmid">23832548</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology. 2014;59:130&#x02013;42.<pub-id pub-id-type="pmid">23832548</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>CX</given-names></name></person-group><article-title>The role of TGF-&#x003b2;/SMAD4 signaling in cancer</article-title><source>Int J Biol Sci</source><year>2018</year><volume>14</volume><fpage>111</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.7150/ijbs.23230</pub-id><pub-id pub-id-type="pmid">29483830</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Zhao M, Mishra L, Deng CX. The role of TGF-&#x003b2;/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14:111&#x02013;23.<pub-id pub-id-type="pmid">29483830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>GZ</given-names></name><name><surname>Guo</surname><given-names>DD</given-names></name><name><surname>Bai</surname><given-names>RX</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>SY</given-names></name></person-group><article-title>Deletion of Smad4 reduces hepatic inflammation and fibrogenesis during nonalcoholic steatohepatitis progression</article-title><source>J Dig Dis</source><year>2018</year><volume>19</volume><fpage>301</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1111/1751-2980.12599</pub-id><pub-id pub-id-type="pmid">29696816</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Qin G, Wang GZ, Guo DD, Bai RX, Wang M, Du SY. Deletion of Smad4 reduces hepatic inflammation and fibrogenesis during nonalcoholic steatohepatitis progression. J Dig Dis. 2018;19:301&#x02013;13.<pub-id pub-id-type="pmid">29696816</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>AJ</given-names></name><name><surname>Chetty</surname><given-names>R</given-names></name></person-group><article-title>Smad4/DPC4</article-title><source>J Clin Pathol</source><year>2018</year><volume>71</volume><fpage>661</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2018-205095</pub-id><pub-id pub-id-type="pmid">29720405</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">McCarthy AJ, Chetty R. Smad4/DPC4. J Clin Pathol. 2018;71:661&#x02013;4.<pub-id pub-id-type="pmid">29720405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwald</surname><given-names>J</given-names></name><name><surname>Vega</surname><given-names>ME</given-names></name><name><surname>Allendorph</surname><given-names>GP</given-names></name><name><surname>Fischer</surname><given-names>WH</given-names></name><name><surname>Vale</surname><given-names>W</given-names></name><name><surname>Choe</surname><given-names>S</given-names></name></person-group><article-title>A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors</article-title><source>Mol Cell</source><year>2004</year><volume>15</volume><fpage>485</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.07.011</pub-id><pub-id pub-id-type="pmid">15304227</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Greenwald J, Vega ME, Allendorph GP, Fischer WH, Vale W, Choe S. A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol Cell. 2004;15:485&#x02013;9.<pub-id pub-id-type="pmid">15304227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Matboli M, Gadallah SH, Rashed WM, Hasanin AH, Essawy N, Ghanem HM, et al. mRNA-miRNA-lncRNA regulatory network in nonalcoholic fatty liver disease. Int J Mol Sci. 2021;22:6770.</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Salah</surname><given-names>N</given-names></name><name><surname>Eissa</surname><given-names>S</given-names></name><name><surname>Mansour</surname><given-names>A</given-names></name><name><surname>El Magd</surname><given-names>NMA</given-names></name><name><surname>Hasanin</surname><given-names>AH</given-names></name><name><surname>El Mahdy</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Evaluation of the role of kefir in management of non-alcoholic steatohepatitis rat model via modulation of NASH linked mRNA-miRNA panel</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><fpage>236</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-27353-x</pub-id><pub-id pub-id-type="pmid">36604518</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Salah N, Eissa S, Mansour A, El Magd NMA, Hasanin AH, El Mahdy MM, et al. Evaluation of the role of kefir in management of non-alcoholic steatohepatitis rat model via modulation of NASH linked mRNA-miRNA panel. Sci Rep. 2023;13:236.<pub-id pub-id-type="pmid">36604518</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HY</given-names></name><name><surname>Oh</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>EK</given-names></name><name><surname>Jung</surname><given-names>HS</given-names></name><name><surname>Jun</surname><given-names>HS</given-names></name></person-group><article-title>Amelioration of high fat diet-induced glucose intolerance by blockade of Smad4 in pancreatic beta-cells</article-title><source>Exp Clin Endocrinol Diab</source><year>2015</year><volume>123</volume><fpage>221</fpage><lpage>6</lpage></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Li HY, Oh YS, Lee YJ, Lee EK, Jung HS, Jun HS. Amelioration of high fat diet-induced glucose intolerance by blockade of Smad4 in pancreatic beta-cells. Exp Clin Endocrinol Diab. 2015;123:221&#x02013;6.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Wei M, Yan X, Xin X, Chen H, Hou L, Zhang J. Hepatocyte-specific smad4 deficiency alleviates liver fibrosis via the p38/p65 pathway. Int J Mol Sci. 2022;23:11696.</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Chiwanda Kaminga</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Wen</surname><given-names>SW</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name></person-group><article-title>Chemokines in non-alcoholic fatty liver disease: a systematic review and network meta-analysis</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>1802</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01802</pub-id><pub-id pub-id-type="pmid">33042108</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Pan X, Chiwanda Kaminga A, Liu A, Wen SW, Chen J, Luo J. Chemokines in non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Front Immunol. 2020;11:1802.<pub-id pub-id-type="pmid">33042108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>T</given-names></name></person-group><article-title>Identification of key genes and pathways in mild and severe nonalcoholic fatty liver disease by integrative analysis</article-title><source>Chronic Dis Transl Med</source><year>2021</year><volume>7</volume><fpage>276</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">34786546</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Feng J, Wei T, Cui X, Wei R, Hong T. Identification of key genes and pathways in mild and severe nonalcoholic fatty liver disease by integrative analysis. Chronic Dis Transl Med. 2021;7:276&#x02013;86.<pub-id pub-id-type="pmid">34786546</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>HM</given-names></name><name><surname>Lai</surname><given-names>TH</given-names></name><name><surname>Li</surname><given-names>CH</given-names></name><name><surname>Wu</surname><given-names>WB</given-names></name></person-group><article-title>TNF-&#x003b1; induces CXCL1 chemokine expression and release in human vascular endothelial cells in vitro via two distinct signaling pathways</article-title><source>Acta Pharm Sin</source><year>2014</year><volume>35</volume><fpage>339</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/aps.2013.182</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Lo HM, Lai TH, Li CH, Wu WB. TNF-&#x003b1; induces CXCL1 chemokine expression and release in human vascular endothelial cells in vitro via two distinct signaling pathways. Acta Pharm Sin. 2014;35:339&#x02013;50.</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Hua</surname><given-names>J</given-names></name></person-group><article-title>Effect of modulation of PPAR-&#x003b3; activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>44612</fpage><pub-id pub-id-type="doi">10.1038/srep44612</pub-id><pub-id pub-id-type="pmid">28300213</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Luo W, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-&#x003b3; activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep. 2017;7:44612.<pub-id pub-id-type="pmid">28300213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Gui</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hepatocyte TGF-&#x003b2; signaling inhibiting WAT browning to promote NAFLD and obesity is associated with let-7b-5p</article-title><source>Hepatol Commun</source><year>2022</year><volume>6</volume><fpage>1301</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/hep4.1892</pub-id><pub-id pub-id-type="pmid">35018737</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhao J, Hu L, Gui W, Xiao L, Wang W, Xia J, et al. Hepatocyte TGF-&#x003b2; signaling inhibiting WAT browning to promote NAFLD and obesity is associated with let-7b-5p. Hepatol Commun. 2022;6:1301&#x02013;21.<pub-id pub-id-type="pmid">35018737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pathogenesis of non-alcoholic fatty liver disease mediated by YAP</article-title><source>Hepatol Int</source><year>2018</year><volume>12</volume><fpage>26</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s12072-017-9841-y</pub-id><pub-id pub-id-type="pmid">29330836</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Chen P, Luo Q, Huang C, Gao Q, Li L, Chen J, et al. Pathogenesis of non-alcoholic fatty liver disease mediated by YAP. Hepatol Int. 2018;12:26&#x02013;36.<pub-id pub-id-type="pmid">29330836</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Inokuchi</surname><given-names>S</given-names></name><name><surname>Roh</surname><given-names>YS</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Loomba</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Transforming growth factor-&#x003b2; signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1</article-title><source>Gastroenterology</source><year>2013</year><volume>144</volume><fpage>1042</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.01.056</pub-id><pub-id pub-id-type="pmid">23391818</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, et al. Transforming growth factor-&#x003b2; signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology. 2013;144:1042&#x02013;1054.<pub-id pub-id-type="pmid">23391818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Kundu A, Dey P, Park JH, Kim IS, Kwack SJ, Kim HS. EX-527 prevents the progression of high-fat diet-induced hepatic steatosis and fibrosis by upregulating SIRT4 in Zucker rats. Cells 2020; 9:1101.</mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Brunt</surname><given-names>EM</given-names></name><name><surname>Kleiner</surname><given-names>DE</given-names></name><name><surname>Kowdley</surname><given-names>KV</given-names></name><name><surname>Chalasani</surname><given-names>N</given-names></name><name><surname>Lavine</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Endpoints and clinical trial design for nonalcoholic steatohepatitis</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><fpage>344</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/hep.24376</pub-id><pub-id pub-id-type="pmid">21520200</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344&#x02013;53.<pub-id pub-id-type="pmid">21520200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Cobbina</surname><given-names>E</given-names></name><name><surname>Akhlaghi</surname><given-names>F</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters</article-title><source>Drug Metab Rev</source><year>2017</year><volume>49</volume><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1080/03602532.2017.1293683</pub-id><pub-id pub-id-type="pmid">28303724</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197&#x02013;211.<pub-id pub-id-type="pmid">28303724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Harris</surname><given-names>EN</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name></person-group><article-title>Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis</article-title><source>Adv Drug Deliv Rev</source><year>2021</year><volume>176</volume><fpage>113869</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.113869</pub-id><pub-id pub-id-type="pmid">34280515</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kumar S, Duan Q, Wu R, Harris EN, Su Q. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev. 2021;176:113869.<pub-id pub-id-type="pmid">34280515</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Korbecki J, G&#x00105;ssowska-Dobrowolska M, W&#x000f3;jcik J, Szatkowska I, Barczak K, Chlubek M, et al. The importance of CXCL1 in physiology and noncancerous diseases of bone, bone marrow, muscle and the nervous system. Int J Mol Sci. 2022;23:4205.</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Korbecki J, Barczak K, Gutowska I, Chlubek D, Baranowska-Bosiacka I. CXCL1: gene, promoter, regulation of expression, mRNA stability, regulation of activity in the intercellular space. Int J Mol Sci<italic>.</italic> 2022;23:792.</mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>MJ</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><fpage>1070</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1002/hep.27921</pub-id><pub-id pub-id-type="pmid">26033752</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Chang B, Xu MJ, Zhou Z, Cai Y, Li M, Wang W, et al. Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1. Hepatology. 2015;62:1070&#x02013;85.<pub-id pub-id-type="pmid">26033752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Shieh</surname><given-names>JM</given-names></name><name><surname>Tsai</surname><given-names>YJ</given-names></name><name><surname>Tsou</surname><given-names>CJ</given-names></name><name><surname>Wu</surname><given-names>WB</given-names></name></person-group><article-title>CXCL1 regulation in human pulmonary epithelial cells by tumor necrosis factor</article-title><source>Cell Physiol Biochem</source><year>2014</year><volume>34</volume><fpage>1373</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1159/000366344</pub-id><pub-id pub-id-type="pmid">25301363</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Shieh JM, Tsai YJ, Tsou CJ, Wu WB. CXCL1 regulation in human pulmonary epithelial cells by tumor necrosis factor. Cell Physiol Biochem. 2014;34:1373&#x02013;84.<pub-id pub-id-type="pmid">25301363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KJ</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name></person-group><article-title>Macrophages in the pathogenesis of atherosclerosis</article-title><source>Cell</source><year>2011</year><volume>145</volume><fpage>341</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.04.005</pub-id><pub-id pub-id-type="pmid">21529710</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341&#x02013;55.<pub-id pub-id-type="pmid">21529710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Cutolo</surname><given-names>M</given-names></name><name><surname>Campitiello</surname><given-names>R</given-names></name><name><surname>Gotelli</surname><given-names>E</given-names></name><name><surname>Soldano</surname><given-names>S</given-names></name></person-group><article-title>The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>867260</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.867260</pub-id><pub-id pub-id-type="pmid">35663975</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Cutolo M, Campitiello R, Gotelli E, Soldano S. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol. 2022;13:867260.<pub-id pub-id-type="pmid">35663975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>MM</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Parhar</surname><given-names>KS</given-names></name><name><surname>Johnston</surname><given-names>MJ</given-names></name><name><surname>Van Rooijen</surname><given-names>N</given-names></name><name><surname>Beck</surname><given-names>PL</given-names></name><etal/></person-group><article-title>In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>1395</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.12.041</pub-id><pub-id pub-id-type="pmid">20044996</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Hunter MM, Wang A, Parhar KS, Johnston MJ, Van Rooijen N, Beck PL, et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology. 2010;138:1395&#x02013;405.<pub-id pub-id-type="pmid">20044996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Lanthier</surname><given-names>N</given-names></name><name><surname>Molendi-Coste</surname><given-names>O</given-names></name><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>van</surname></name><name><surname>Rooijen</surname><given-names>N</given-names></name><name><surname>Horsmans</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet</article-title><source>FASEB J</source><year>2011</year><volume>25</volume><fpage>4301</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1096/fj.11-189472</pub-id><pub-id pub-id-type="pmid">21873555</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lanthier N, Molendi-Coste O, Cani PD, van, Rooijen N, Horsmans Y, et al. Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet. FASEB J. 2011;25:4301&#x02013;11.<pub-id pub-id-type="pmid">21873555</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Marra</surname><given-names>F</given-names></name><name><surname>Tacke</surname><given-names>F</given-names></name></person-group><article-title>Roles for chemokines in liver disease</article-title><source>Gastroenterology</source><year>2014</year><volume>147</volume><fpage>577</fpage><lpage>94.e571</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.06.043</pub-id><pub-id pub-id-type="pmid">25066692</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577&#x02013;94.e571.<pub-id pub-id-type="pmid">25066692</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>K</given-names></name><name><surname>Kodama</surname><given-names>Y</given-names></name><name><surname>Inokuchi</surname><given-names>S</given-names></name><name><surname>Schnabl</surname><given-names>B</given-names></name><name><surname>Aoyama</surname><given-names>T</given-names></name><name><surname>Ohnishi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>323</fpage><lpage>34.e327</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.03.052</pub-id><pub-id pub-id-type="pmid">20347818</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139:323&#x02013;34.e327.<pub-id pub-id-type="pmid">20347818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Stienstra</surname><given-names>R</given-names></name><name><surname>Saudale</surname><given-names>F</given-names></name><name><surname>Duval</surname><given-names>C</given-names></name><name><surname>Keshtkar</surname><given-names>S</given-names></name><name><surname>Groener</surname><given-names>JE</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>511</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/hep.23337</pub-id><pub-id pub-id-type="pmid">20054868</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JE, van Rooijen N, et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology. 2010;51:511&#x02013;22.<pub-id pub-id-type="pmid">20054868</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Nowicki</surname><given-names>KW</given-names></name><name><surname>Hosaka</surname><given-names>K</given-names></name><name><surname>Walch</surname><given-names>FJ</given-names></name><name><surname>Scott</surname><given-names>EW</given-names></name><name><surname>Hoh</surname><given-names>BL</given-names></name></person-group><article-title>M1 macrophages are required for murine cerebral aneurysm formation</article-title><source>J Neurointerv Surg</source><year>2018</year><volume>10</volume><fpage>93</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1136/neurintsurg-2016-012911</pub-id><pub-id pub-id-type="pmid">28196918</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Nowicki KW, Hosaka K, Walch FJ, Scott EW, Hoh BL. M1 macrophages are required for murine cerebral aneurysm formation. J Neurointerv Surg. 2018;10:93&#x02013;97.<pub-id pub-id-type="pmid">28196918</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Niswender</surname><given-names>KD</given-names></name><name><surname>Jetton</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Moates</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>305</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.1.305</pub-id><pub-id pub-id-type="pmid">9867845</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274:305&#x02013;15.<pub-id pub-id-type="pmid">9867845</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>